Mark Zitter Addresses How Oncology Payers Are Becoming Stricter About Covered Therapies

Reflecting on 15 Years of Health IT Evolution and What’s Next: Nate C. Apathy, PhD

January 27th 2026

Dexamethasone Before R-CHOP in DLBCL With GI Involvement Can Limit Complications, Retain Efficacy

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Listen

January 25th 2026

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

Dexamethasone pretreatment significantly reduces GI complications in DLBCL patients undergoing R-CHOP, maintaining efficacy and improving safety.

January 20th 2026

Teclistamab Transforms Early Myeloma Care: Roberto Mina, MD

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

Roberto Mina, MD, Winship Cancer Institute of Emory University

CCCA Associated With Longer Time to Diagnosis vs Other Scarring Alopecias

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple myeloma, explained Roberto Mina, MD.

The findings reinforce the need for earlier recognition of scarring alopecias—particularly CCCA—and improved education for clinicians. | Image Credit: cattyphoto - stock.adobe.com

Addressing the Fragmentation of MS Care: Kavita Nair, PhD

Central centrifugal cicatricial alopecia (CCCA) faces significant diagnostic delays, highlighting the need for increased awareness and education among providers.

Related Content

January 30th 2026

Reflecting on 15 Years of Health IT Evolution and What’s Next: Nate C. Apathy, PhD

January 27th 2026

Dexamethasone Before R-CHOP in DLBCL With GI Involvement Can Limit Complications, Retain Efficacy

Nate C. Apathy, PhD, guest editor of AJMC's 15th Health IT special issue, calls for tools to be closely aligned with user needs.

Listen

January 25th 2026

Transparency in Coverage Data to Expose Ghost Rates and Hold Payers Accountable: David Muhlestein, PhD

Dexamethasone pretreatment significantly reduces GI complications in DLBCL patients undergoing R-CHOP, maintaining efficacy and improving safety.

January 20th 2026

Teclistamab Transforms Early Myeloma Care: Roberto Mina, MD

David Muhlestein, PhD, breaks down ghost rates, data gaps, and why stronger oversight is needed to make Transparency in Coverage files usable for patients.

Listen

CCCA Associated With Longer Time to Diagnosis vs Other Scarring Alopecias

The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple myeloma, explained Roberto Mina, MD.